妊娠期间发生的霍奇金淋巴瘤 (HL) 是一种罕见疾病，其治疗依赖于稀少的文献。妊娠的特殊性要求临床医生考虑临床紧急情况、淋巴瘤的阶段、妊娠的三个月以及患者的选择。主要目标是双重的：限制母亲和胎儿的毒性和不良事件的风险，而不降低成功结果的机会。目前的文献数据表明，使用 ABVD 型多化疗（阿霉素、博莱霉素、长春花碱、达卡巴嗪）与产科事件和长期胎儿毒性有关。我们在此报告考虑观望、长春花碱单药治疗和 ABVD 联合化疗方案的均质管理结果。产科并发症、缓解率和总生存率 (100%) 方面的结果强化了这样一种观点，即不涉及使用多种药物治疗的策略是可能的，并且与非常好的结果相关。版权所有 © 2024。由 Elsevier B.V. 出版。

Hodgkin lymphoma (HL) occuring during pregnancy is a rare condition, and management relies on sparse literature. The specificity of pregnancy requires the clinician to take into account the clinical emergency, the stage of the lymphoma, the trimester of pregnancy, and the patient's choices. The main objective is twofold: to limit the risk of toxicity and adverse events for both mother and fetus, without reducing the chances of a successful outcome. Current literature data suggest that the use of ABVD-type polychemotherapy (adriamycin, bleomycin, vinblastine, dacarbazine) is associated with obstetrical events and long-term fetal toxicity. We report here the results of a homogeneous management considering wait-and-see, vinblastine monotherapy and ABVD polychemotherapy options. The outcomes in terms of obstetrical complications, response rate, and overall survival (100%) reinforce the idea that strategies that do not involve the use of multidrug therapy are possible and are associated with very good results.Copyright © 2024. Published by Elsevier B.V.